PT  - JOURNAL ARTICLE
AU  - Roya M. Dayam
AU  - Jaclyn C. Law
AU  - Rogier L. Goetgebuer
AU  - Gary Y. C. Chao
AU  - Kento T. Abe
AU  - Mitchell Sutton
AU  - Naomi Finkelstein
AU  - Joanne M. Stempak
AU  - Daniel Pereira
AU  - David Croitoru
AU  - Lily Acheampong
AU  - Saima Rizwan
AU  - Klaudia Rymaszewski
AU  - Raquel Milgrom
AU  - Darshini Ganatra
AU  - Nathalia V. Batista
AU  - Melanie Girard
AU  - Irene Lau
AU  - Ryan Law
AU  - Michelle W. Cheung
AU  - Bhavisha Rathod
AU  - Julia Kitaygorodsky
AU  - Reuben Samson
AU  - Queenie Hu
AU  - W. Rod Hardy
AU  - Nigil Haroon
AU  - Robert D. Inman
AU  - Vincent Piguet
AU  - Vinod Chandran
AU  - Mark S. Silverberg
AU  - Anne-Claude Gingras
AU  - Tania H. Watts
TI  - Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases
AID  - 10.1101/2022.01.26.22269856
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.26.22269856
4099  - http://medrxiv.org/content/early/2022/02/28/2022.01.26.22269856.short
4100  - http://medrxiv.org/content/early/2022/02/28/2022.01.26.22269856.full
AB  - Background Limited information is available on the impact of immunosuppressants on COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMID).Methods This observational cohort study examined the immunogenicity of SARS-CoV-2 mRNA vaccines in adult patients with inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, or psoriatic disease, with or without maintenance immunosuppressive therapies. Antibody and T cell responses to SARS-COV-2, including neutralization against SARS-CoV-2 variants were determined before and after 1 and 2 vaccine doses.Results We prospectively followed 150 subjects, 26 healthy controls, 9 IMID patients on no treatment, 44 on anti-TNF, 16 on anti-TNF with methotrexate/azathioprine (MTX/AZA), 10 on anti-IL-23, 28 on anti-IL-12/23, 9 on anti-IL-17, and 8 on MTX/AZA. Antibody and T cell responses to SARS-CoV-2 were detected in all participants, increasing from dose 1 to dose 2 and declining 3 months later, with greater attrition in IMID patients compared to healthy controls. Antibody levels and neutralization efficacy against variants of concern were substantially lower in anti-TNF treated patients than in healthy controls and were undetectable against Omicron by 3 months after dose 2.Conclusions Our findings support the need for a third dose of mRNA vaccine and for continued monitoring of immunity in these patient groups.Funding Funded by a donation from Juan and Stefania Speck and by Canadian Institutes of Health (CIHR) /COVID-Immunity Task Force (CITF) grants VR-1 172711 and VS1-175545 (T.H.W. and A.C.G); CIHR FDN-143250 (T.H.W.), GA2-177716 (V.C., A.C.G., T.W.), GA1-177703 (A.C.G.) and the CIHR rapid response network to SARS-CoV-2 variants, CoVaRR-Net (to A.C.G.).Competing Interest StatementDr Inman has served as consultant for Abbvie, Janssen, Lilly, Novartis and has received research funding support from Abbvie and Novartis. Dr. Piguet has no personal financial ties with any pharmaceutical company. He has received honoraria for speaker and/or advisory board member roles from AbbVie, Almirall, Celgene, Janssen, Kyowa Kirin Co. Ltd, LEO Pharma, Novartis, Pfizer, Sanofi, UCB, and Union Therapeutics. In his role as Department Division Director of Dermatology at the University of Toronto, Dr. Piguet has received departmental support in the form of unrestricted educational grants from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Lilly, L Oreal, NAOS, Novartis, Pfizer, Pierre-Fabre, Sandoz, and Sanofi in the past 36 months. Dr. Chandran has received research grants from AbbVie, Amgen and Eli-Lilly and has received honoraria for advisory board member roles from AbbVie, Amgen, BMS, Eli Lilly, Janssen, Novartis, Pfizer and UCB. His spouse is an employee of AstraZeneca. Dr Silverberg has received research support, consulting fees and speaker honoraria from Abbvie, Janssen, Takeda, Pfizer, Gilead and Amgen. All other authors have no conflicts to declare. Funding StatementFunded by a donation from Juan and Stefania Speck and by Canadian Institutes of Health (CIHR) /COVID-Immunity Task Force (CITF) grants VR-1 172711 and VS1-175545 (T.H.W. and A.C.G); CIHR FDN-143250 (T.H.W.), GA2- 177716 (V.C., A.C.G., T.W.), GA1-177703 (A.C.G.) and the CIHR rapid response network to SARS-CoV-2 variants, CoVaRR-Net (to A.C.G.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the research ethics boards of the University of Toronto (REB protocol #27673), Mount Sinai Hospital/Sinai Health System (MSH REB #21-0022-E), University Health Network-Toronto Western Hospital division (REB # 21-5096) and Womens College Hospital (REB approval 2021-0023-E).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the present study are available upon reasonable request to the authors